ArticleJournal of neuro-oncology2025
Local cranial radiation combined with third-generation tyrosine kinase inhibitors improve leptomeningeal metastasis disease-free survival in patients with EGFR-mutated non-small cell lung cancer and brain metastasis.
Article in Journal of neuro-oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Risk factors for short-term survival inTranslational cancer research · 2026Article
- Treatment decision-making for leptomeningeal metastasis after TKI resistance in EGFR-mutant lung cancer: a comprehensive review on staging, resistance patterns, and multimodal interventions.Frontiers in neurologyReview
Corrections and comments
- Erratum issued
Authors and funding
10 authors.
Funding
Abstract
purposeThe role of local cranial radiation (LCR) combined with third-generation tyrosine kinase inhibitors (TKIs) in the following the progression to leptomeningeal metastasis (LM) in epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) with brain metastasis (BM) remains unclear. This study investigates whether LCR combined with third-generation TKIs can influence the occurrence LM in EGFR-mutated NSCLC with BM.
methodsPatients diagnosed with EGFR exon 19del or exon 21 L858R mutant NSCLC with LM in Guangdong Sanjiu Brain Hospital were recruited into the study between January 1, 2018 and December 31, 2023. They were separated into two groups according to whether they received LCR during the period from BM to LM on not. The primary endpoints were the LM disease-free survival (LM-DFS) and LM rate.
resultsA total of 93 patients were enrolled, 60 in the TKIs group and 33 in the LCR + TKIs group. The median LM-DFS of the TKIs group and the LCR + TKIs group were 14.1 months (95% CI 12.3-19.8 months) and 27.0 months (95% CI 19.4-35.1 months), respectively (p < 0.01). After propensity score matching, the median LM-DFS were 13.2 months (95% CI 9.5-21.6 months) and 24.6 months (95% CI 18.1-35.1 months), respectively (p = 0.01). 2-year LM rates in TKIs group and LCR + TKIs group were 78.3% and 45.5% in all patients (p < 0.01); 76.9% and 50.0% in matched cohort (p = 0.02), respectively.
conclusionLCR combined with third-generation TKIs could improve LM-DFS and decrease 2-year LM rate compared with third-generation TKIs alone. Further studies are required to ascertain this effect.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.